The Motley Fool

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?

Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...
CNBC

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...
Hosted on MSN

Master recursion and speed up Python code

Recursion is more than a coding trick—it’s a powerful way to simplify complex problems in Python. From elegant tree traversals to backtracking algorithms, mastering recursion opens the door to cleaner ...
Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Reuters

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

NEW YORK, Aug 8 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab, a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival ...